Ionis Pharmaceuticals, Inc.
Modified compounds and uses thereof

Last updated:

Abstract:

The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.

Status:
Grant
Type:

Utility

Filling date:

10 Feb 2021

Issue date:

19 Oct 2021